Edition:
United States

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

7.14USD
20 Jul 2018
Change (% chg)

$-0.27 (-3.64%)
Prev Close
$7.41
Open
$7.50
Day's High
$7.69
Day's Low
$7.11
Volume
259,022
Avg. Vol
319,716
52-wk High
$22.96
52-wk Low
$6.90

Select another date:

Tue, Jun 26 2018

Photo

FDA knocks back Achaogen's drug for bloodstream infection

The U.S. Food and Drug Administration cleared Achaogen Inc's antibiotic to treat adults with complicated urinary tract infections, but shares slumped 25 percent as the drug failed to win approval for treating bloodstream infections.

Achaogen's antibiotic gets FDA nod for urinary tract infections

June 26 The U.S. Food and Drug Administration approved Achaogen Inc's antibiotic to treat adults with complicated urinary tract infections, the company said on Tuesday.

BRIEF-Achaogen Q1 loss per share $1.06

* ACHAOGEN REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Achaogen Says FDA Advisory Committee Voted In Favor Of Plazomicin For Urinary Tract Infections

* ACHAOGEN ANNOUNCES FDA ADVISORY COMMITTEE VOTED UNANIMOUSLY IN FAVOR OF PLAZOMICIN FOR TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT INFECTIONS Source text for Eikon: Further company coverage:

BRIEF-Achaogen Stock Trading Halted Today

* ACHAOGEN STOCK TRADING HALTED TODAY Source text for Eikon: Further company coverage:

BRIEF-Achaogen Says FDA to Review Plazomicin By June 25

* ACHAOGEN ANNOUNCES DATE OF FDA ADVISORY COMMITTEE MEETING FOR PLAZOMICIN

BRIEF-Robert Duggan Reports 14.2 Pct Stake In Achaogen Inc As Of March 12 Compared To A Stake Of 13.2 Pct As Of Dec 6

* ROBERT DUGGAN REPORTS 14.2 PERCENT STAKE IN ACHAOGEN INC AS OF MARCH 12 COMPARED TO A STAKE OF 13.2 PERCENT AS OF DECEMBER 6 -SEC FILING Source text: (http://bit.ly/2DoINbl) Further company coverage:

BRIEF-Achaogen Enters Into New $50 Million Secured Credit Facility With Silicon Valley Bank

* ACHAOGEN ENTERS INTO NEW $50 MILLION SECURED CREDIT FACILITY WITH SILICON VALLEY BANK Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Achaogen Reports Q4 Loss Per Share $0.98

* ACHAOGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Achaogen Announces Upgraded Status For Plazomicin Fill Manufacturer

* SAYS ‍FDA CLASSIFIED OUTCOME OF ITS Q4 2017 REINSPECTION OF PFIZER'S MCPHERSON FACILITY AS VOLUNTARY ACTION INDICATED​ Source text for Eikon: Further company coverage:

Select another date: